This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Healthcare ETFs in Focus as Q3 Earnings Unfold
by Sweta Killa
The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Buy 5 High-Beta ETFs That Still Offer Value
by Sanghamitra Saha
The S&P 500 Index is currently trading at a forward P/E of 20.3X, which is higher than five-year and 10-year average. With holiday season approaching, investors can try these high-beta ETFs with low P/E ratios.
JNJ Posts Mixed Q3 Bag, Ups View: ETFs in Focus
by Sweta Killa
Johnson & Johnson (JNJ) continued its long streak of earnings beat but lagged the revenue estimates. The company lifted its full-year guidance.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data
by Sweta Jaiswal, FRM
The positive data update has put the spotlight on a number of ETFs that could benefit from their high exposure to Johnson & Johnson.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
5 ETF Areas for Investors to Consider Amid the September Slump
by Sweta Jaiswal, FRM
Amid the market uncertainty, we have highlighted some ETF areas that can be good investment options for market participants to combat the September chaos.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
5 ETFs to Combat Stimulus Tapering Concerns, Virus Woes
by Sweta Jaiswal, FRM
Here we discuss some ETFs that seem like good additions to the portfolio given that the present market scenario is largely dominated by Fed's stimulus tapering concerns.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
'Animal Spirits' Show There Feathers
by Daniel Laboe
An elevated level of new daily 52-week highs and lows exemplify a polarizing stock market with an equal mix of hope and fear
5 Hot Equity ETFs of Last Week Amid Volatility
by Sweta Killa
ETFs overall gathered about $18 billion capital last week (Aug 16-19), bringing in inflows of $563.2 billion year to date.
5 ETFs to Bet on Fed's Stimulus Tapering Concerns, Weak Data
by Sweta Jaiswal, FRM
Here we discuss some ETFs that seem like a good addition to the portfolio considering the present market scenario largely dominated by Fed's tapering concerns.
Healthcare ETF (XLV) Hits a New 52-Week High
by Sweta Jaiswal, FRM
The Health Care Select Sector SPDR Fund (XLV) hits a new 52-week high. Are more gains in store?
The Zacks Analyst Blog Highlights: KBE, XMVM, XLB, XLV and PFM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: KBE, XMVM, XLB, XLV and PFM
Stocks at Record: Buy 5 Top Cheap ETFs With High Potential
by Sanghamitra Saha
Wall Street has rallied hard this year on vaccine distribution, a prolonged period of easy money policy, fiscal stimulus and stronger-than-expected earnings.
ETF Asset Report of July
by Sanghamitra Saha
The month of July was moderately upbeat for the S&P500. The month marked the sixth straight monthly gains.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
5 Top-Ranked ETF Winners of July With More Upside Potential
by Sweta Killa
The month of July was marked with huge volatility for Wall Street.